Zacks Research Predicts Bruker's Q4 Earnings (NASDAQ:BRKR)

Bruker Co. (NASDAQ:BRKR - Free Report) - Research analysts at Zacks Research cut their Q4 2026 earnings estimates for shares of Bruker in a note issued to investors on Monday, April 7th. Zacks Research analyst R. Department now expects that the medical research company will post earnings per share of $1.05 for the quarter, down from their prior estimate of $1.07. The consensus estimate for Bruker's current full-year earnings is $2.69 per share.

Several other equities research analysts have also issued reports on the stock. Guggenheim restated a "buy" rating on shares of Bruker in a report on Monday, February 24th. Citigroup decreased their price objective on shares of Bruker from $75.00 to $50.00 and set a "buy" rating for the company in a research note on Monday, April 7th. Barclays cut their target price on Bruker from $60.00 to $50.00 and set an "overweight" rating on the stock in a research note on Thursday. Finally, Stifel Nicolaus decreased their price target on Bruker from $70.00 to $57.00 and set a "hold" rating for the company in a research note on Friday, February 14th. Six equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $66.50.

Bruker Trading Up 1.8 %

BRKR traded up $0.69 during trading on Wednesday, reaching $38.76. The company had a trading volume of 3,139,890 shares, compared to its average volume of 1,467,987. The company has a quick ratio of 0.77, a current ratio of 1.60 and a debt-to-equity ratio of 1.15. Bruker has a 52 week low of $34.10 and a 52 week high of $90.03. The stock has a market cap of $5.88 billion, a P/E ratio of 51.00, a PEG ratio of 2.16 and a beta of 1.18. The business has a 50 day simple moving average of $46.16 and a 200-day simple moving average of $54.75.

Remove Ads

Bruker (NASDAQ:BRKR - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The medical research company reported $0.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.75 by $0.01. Bruker had a return on equity of 21.01% and a net margin of 3.36%.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in BRKR. Alpha Wealth Funds LLC purchased a new stake in shares of Bruker in the 1st quarter worth approximately $230,000. CGN Advisors LLC raised its stake in Bruker by 1.4% in the first quarter. CGN Advisors LLC now owns 22,014 shares of the medical research company's stock worth $919,000 after buying an additional 296 shares in the last quarter. Merit Financial Group LLC lifted its holdings in Bruker by 226.9% during the first quarter. Merit Financial Group LLC now owns 16,722 shares of the medical research company's stock worth $698,000 after buying an additional 11,607 shares during the period. Rhumbline Advisers boosted its position in Bruker by 1.2% during the 1st quarter. Rhumbline Advisers now owns 317,267 shares of the medical research company's stock valued at $13,243,000 after acquiring an additional 3,763 shares in the last quarter. Finally, GAMMA Investing LLC grew its stake in Bruker by 4,299.2% in the first quarter. GAMMA Investing LLC now owns 56,266 shares of the medical research company's stock valued at $2,349,000 after purchasing an additional 54,987 shares during the last quarter. 79.52% of the stock is currently owned by institutional investors.

Bruker Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, March 28th. Investors of record on Monday, March 17th were issued a $0.05 dividend. The ex-dividend date of this dividend was Monday, March 17th. This represents a $0.20 annualized dividend and a dividend yield of 0.52%. Bruker's payout ratio is currently 26.32%.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.